Short Interest in ProQR Therapeutics (NASDAQ:PRQR) Declines By 54.7%

ProQR Therapeutics (NASDAQ:PRQR) saw a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 187,600 shares, a decline of 54.7% from the November 15th total of 413,800 shares. Based on an average daily trading volume, of 1,400,000 shares, the short-interest ratio is presently 0.1 days.

Hedge Funds Weigh In On ProQR Therapeutics

Large investors have recently modified their holdings of the business. BNP Paribas Financial Markets boosted its stake in shares of ProQR Therapeutics by 14.2% in the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 7,300 shares in the last quarter. OneDigital Investment Advisors LLC lifted its holdings in ProQR Therapeutics by 37.0% in the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 15,550 shares during the period. Finally, Privium Fund Management B.V. boosted its position in shares of ProQR Therapeutics by 0.9% during the 3rd quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock worth $10,251,000 after purchasing an additional 51,663 shares in the last quarter. 32.65% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of ProQR Therapeutics in a research report on Thursday. Raymond James upgraded shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their target price for the stock from $6.00 to $14.00 in a research note on Tuesday, October 29th. JMP Securities restated a “market outperform” rating and issued a $8.00 price target on shares of ProQR Therapeutics in a research report on Thursday. StockNews.com downgraded ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. Finally, Chardan Capital reiterated a “buy” rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $7.60.

ProQR Therapeutics Stock Down 14.0 %

NASDAQ PRQR traded down $0.46 during trading hours on Friday, hitting $2.83. 759,070 shares of the stock were exchanged, compared to its average volume of 521,449. The company has a market cap of $231.15 million, a price-to-earnings ratio of -8.84 and a beta of 0.24. ProQR Therapeutics has a 12-month low of $1.61 and a 12-month high of $4.62. The stock has a 50-day moving average of $3.39 and a 200 day moving average of $2.38.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).